<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Ther Nucleic Acids</journal-id><journal-id journal-id-type="iso-abbrev">Mol Ther Nucleic Acids</journal-id><journal-title-group><journal-title>Molecular Therapy. Nucleic Acids</journal-title></journal-title-group><issn pub-type="epub">2162-2531</issn><publisher><publisher-name>American Society of Gene &#x00026; Cell Therapy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31927328</article-id><article-id pub-id-type="pmc">6953771</article-id><article-id pub-id-type="publisher-id">S2162-2531(19)30385-3</article-id><article-id pub-id-type="doi">10.1016/j.omtn.2019.11.027</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>LINC01413/hnRNP-K/ZEB1 Axis Accelerates Cell Proliferation and EMT in Colorectal Cancer via Inducing YAP1/TAZ1 Translocation</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Ji</surname><given-names>Ling</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Li</surname><given-names>Xiang</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Zhou</surname><given-names>Zhenhua</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Zheng</surname><given-names>Zhihai</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Jin</surname><given-names>Li</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Jiang</surname><given-names>Feizhao</given-names></name><email>feizhaojiang_zfz@163.com</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>1</label>The First Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China</aff><aff id="aff2"><label>2</label>Zhejiang Provincial Key Laboratory of Medical Genetics, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author: Feizhao Jiang, The First Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325035, China. <email>feizhaojiang_zfz@163.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>29</day><month>11</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><day>06</day><month>3</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>29</day><month>11</month><year>2019</year></pub-date><volume>19</volume><fpage>546</fpage><lpage>561</lpage><history><date date-type="received"><day>3</day><month>2</month><year>2019</year></date><date date-type="accepted"><day>18</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 The Authors</copyright-statement><copyright-year>2019</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><p>Long non-coding RNAs (lncRNAs) are crucial molecules in tumorigenesis and tumor growth in various human cancers, including colorectal cancer (CRC). Studies have revealed that lncRNAs can regulate cellular processes in cancers by interacting with proteins, for example RNA-binding proteins (RBPs). In this study, we recognize a novel lncRNA called LINC01413 that is upregulated in CRC tissues through lncRNAs microarray. Subsequently, we confirmed that an elevated level of LINC01413 expression in CRC tissues was strongly correlated to clinicopathological features, such as tumor size, tumor stage, lymph node metastasis, and distant metastasis, and its association with poor overall survival was also revealed. Additionally, LINC01413 facilitates cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) <italic>in&#x000a0;vitro</italic>. Also, silenced LINC01413 restrains tumor growth <italic>in&#x000a0;vivo</italic>. Moreover, LINC01413 binds with hnRNP-K and induces YAP1 (yes-associated protein 1)/TAZ1 (tafazzin) nuclear translocation to regulate the expression of ZEB1 in CRC cells. Taken together, this research suggested LINC01413 as a positive regulator in CRC progression through the LINC01413/hnRNP-K/TAZ1/YAP1/ZEB1 axis, broadening a new view on CRC treatment.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>LINC01413</kwd><kwd>ZEB1</kwd><kwd>YAP1/TAZ1</kwd><kwd>hnRNP-K</kwd><kwd>CRC</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p id="p0010">Colorectal cancer (CRC) is the third most prevalent and lethal type of malignancy in the world.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Despite great improvements in diagnostic and therapeutic techniques, the prognosis of CRC patients remains poor.<xref rid="bib2" ref-type="bibr">2</xref>, <xref rid="bib3" ref-type="bibr">3</xref>, <xref rid="bib4" ref-type="bibr">4</xref> Actually, about 90% of mortality from CRC is due to distant metastasis, and epithelial-mesenchymal transition (EMT) is noted as the major contributing factor of metastasis.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref></p><p id="p0015">Long non-coding RNAs (lncRNAs) are transcripts with more than 200 nt that have no protein-coding potential.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> Increasing evidence has illustrated that lncRNAs are involved in many diseases and that dysregulation of lncRNAs contributes to tumorigenesis in various cancers.<xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref> Recently, lncRNAs have been reported as an EMT modulator in cancers. For instance, lncRNA plays important roles in the EMT process in ovarian cancer.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> lncRNA XLOC_000647 exerts functions in EMT-induced cell invasion via downregulating NLRP3.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> In addition, several lncRNAs have also been proven to influence EMT in CRC. As an example, TUG1 triggers EMT in CRC by prompting KIAA1199 expression via miR-600.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> Also, LINC01133 restrains EMT and metastasis in CRC by interacting with SRSF6.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> LINC01413 is a novel lncRNA that locates in 15q21.3, and its role or function in CRC remains unclear.</p><p id="p0020">The EMT, once thought to be essential during embryonic development, has been increasingly reported in human cancers recently due to its role in tumor invasion and metastasis.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> The full process of EMT involves a complex genetic program, including losing epithelial character and acquiring mesenchymal and motility properties.<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> Normal or tumor epithelial cells initiate EMT once separated from their neighbors and migrating away.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> There are several factors that have been regarded as main regulators of EMT, such as Snail, ZEB, and Twist families.<xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref> Additionally, the expression of these regulators is stringently modulated by various cell-intrinsic pathways and extracellular signals in the processes of transcription and translation, as well as protein stability control.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> Moreover, recent studies have certified that lncRNAs or microRNAs (miRNAs) could also regulate the occurrence of EMT.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> For example, lincRNA-ROR is an EMT inducer and a contributor to the tumorigenesis and metastasis of breast cancer.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> However, the regulation network of EMT is still not well understood, and thus it requires further study.</p><p id="p0025">The Hippo pathway is evidenced as typical anti-tumor signaling during cancer development.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> Activation of this pathway is determined by the phosphorylation of two core factors, YAP1 (yes associated protein 1) and TAZ1 (tafazzin).<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> YAP and TAZ are critical transcriptional regulators that are pervasively activated and essential for the initiation and development of human malignancies.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> Normally, YAP and TAZ are phosphorylated by LATS1 or LATS2 so that they are unable to translocate into nucleus, leading to transrepression of their targets, which play a role during tumorigenesis and cancer progression.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> Furthermore, the Hippo pathway has also been revealed to exert important functions in intestinal disease, including CRC.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref></p><p id="p0030">In this study, we investigated the specific role as well as the potential mechanism of LINC01413 in CRC.</p></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>LINC01413 Is Upregulated in CRC Tissues and Cell Lines and Indicates Poor Prognosis for CRC Patients</title><p id="p0035">To explore the transcriptome changes in CRC, total RNAs obtained from three pairs of CRC tissues and corresponding normal tissues were analyzed by using high-throughput RNA sequencing. We revealed that a total of 473 lncRNAs are differentially expressed, among which 43 exhibit more than 15-fold variation, including 26 lncRNAs with high expression and 17 lncRNAs with low expression (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A). Then, we tested the five most upregulated lncRNAs among the 26 above-mentioned candidates in CRC cell lines, including LINC01413, LINC02043, LINC01836, MIR4713, and LRP1-AS. As a result, LINC01413 and LINC02043 were found to be highly expressed while the other three genes changed little in five CRC cell lines compared to the normal colon epithelial cell line NCM460 (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>B). Based on these results, we further explored the role of LINC01413 in CRC, which exhibited the highest expression in CRC cell lines among the five lncRNAs detected.<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>LINC01413 Is Upregulated in CRC Tissues and Cell Lines and Indicates Poor Prognosis for CRC Patients</p><p>(A) High-throughput RNA sequencing of total cellular RNA obtained from three pairs of CRC tissues and corresponding normal tissues was performed to explore the transcriptome changes in CRC. (B) Quantitative real-time PCR results of the expression of the five most altered lncRNAs in CRC cell lines. (C) Relative high level of LINC01413 was determined in CRC cells compared with normal NCM460 cell. Result was obtained using quantitative real-time PCR. (D) Quantitative real-time PCR detected the higher LINC01413 expression in CRC tissues than that in non-tumor tissues. (E) The expression levels of LINC01413 in tissues with or without distant metastasis were accessed by quantitative real-time PCR. (F) LINC01413 expression in different TNM stages of CRC was evaluated by quantitative real-time PCR. (G) Kaplan-Meier analysis (log-rank test) was used to estimate the relationship between LINC01413 expression and overall survival of CRC patients. Error bars show the mean&#x000a0;&#x000b1;&#x000a0;SD of more than three independent experiments. *p&#x000a0;&#x0003c; 0.05, **p&#x000a0;&#x0003c; 0.01 versus control group.</p></caption><graphic xlink:href="gr1"/></fig></p><p id="p0040">First, we proved again that LINC01413 expression is notably enhanced in CRC cell lines (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C). Furthermore, we also observed LINC01413 upregulation in 92 of the CRC tissues in comparison with paired non-tumor tissues (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>D). In addition, CRC tissues with distant metastasis showed higher levels of LINC01413 expression than did those without distant metastasis (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>E). Moreover, LINC01413 level seemed to be closely related to TNM (tumor, node, metastasis) stages because patients at a more advanced stage usually expressed a high LINC01413 level in contrast to those at earlier stages (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>F). These data suggest that LINC01413 may function as an oncogene in CRC.</p><p id="p0045">To further analyze the role of LINC01413 in CRC, the 92 CRC patients with multiple clinicopathological characteristics were divided into two groups according to high (n&#x000a0;= 49) or low (n&#x000a0;= 43) LINC01413 expression. As shown in <xref rid="tbl1" ref-type="table">Table 1</xref>, high levels of LINC01413 were accompanied with large tumor size (p&#x000a0;= 0.002), higher TNM stage (p&#x000a0;= 0.006), lymph node metastasis (p&#x000a0;= 0.036), and distant metastasis (p&#x000a0;= 0.019) in patients, whereas its expression hardly correlated with age or sex. Moreover, the Cox proportional hazards model applied in multivariate analysis elucidated that LINC01413 expression (p&#x000a0;= 0.034) can serve as an independent predictor for CRC prognosis, as can TNM stage (p&#x000a0;= 0.032) and lymph node metastasis (p&#x000a0;= 0.019) (<xref rid="tbl2" ref-type="table">Table 2</xref>). Furthermore, the results of Kaplan-Meier analysis and a log-rank test implied that higher LINC01413 expression tended to lead to poorer overall survival (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>G). These observations suggested that enhanced LINC01413 may play a role in the progression of&#x000a0;CRC.<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Correlation between LINC01413 Expression and Clinical Features of CRC Patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Variable</th><th colspan="2">LINC01413 Expression<hr/></th><th rowspan="2">p Value</th></tr><tr><th>Low</th><th>High</th></tr></thead><tbody><tr><td colspan="4"><bold>Age (Years)</bold></td></tr><tr><td colspan="4"><hr/></td></tr><tr><td>&#x000a0;6</td><td>34</td><td>31</td><td rowspan="2">0.113<hr/></td></tr><tr><td>&#x000a0;&#x02265;60</td><td>9</td><td>18</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td colspan="4"><bold>Sex</bold></td></tr><tr><td colspan="4"><hr/></td></tr><tr><td>&#x000a0;Male</td><td>14</td><td>14</td><td rowspan="2">0.821<hr/></td></tr><tr><td>&#x000a0;Female</td><td>29</td><td>35</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td colspan="4"><bold>Tumor Size (cm)</bold></td></tr><tr><td colspan="4"><hr/></td></tr><tr><td>&#x000a0;&#x02264;5</td><td>28</td><td>15</td><td rowspan="2">0.002<hr/></td></tr><tr><td>&#x000a0;5</td><td>15</td><td>34</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td colspan="4"><bold>TNM Stage</bold></td></tr><tr><td colspan="4"><hr/></td></tr><tr><td>&#x000a0;I&#x02013;II</td><td>25</td><td>14</td><td rowspan="2">0.006<hr/></td></tr><tr><td>&#x000a0;III&#x02013;IV</td><td>18</td><td>35</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td colspan="4"><bold>Lymph Node Metastasis</bold></td></tr><tr><td colspan="4"><hr/></td></tr><tr><td>&#x000a0;Negative</td><td>27</td><td>19</td><td/></tr><tr><td>&#x000a0;Positive</td><td>16</td><td>30</td><td>0.036</td></tr><tr><td colspan="4"><hr/></td></tr><tr><td colspan="4"><bold>Distant Metastasis</bold></td></tr><tr><td colspan="4"><hr/></td></tr><tr><td>&#x000a0;Negative</td><td>23</td><td>14</td><td>0.019</td></tr><tr><td>&#x000a0;Positive</td><td>20</td><td>35</td><td/></tr></tbody></table><table-wrap-foot><fn><p>Low/high by the sample mean. Pearson &#x003c7;<sup>2</sup> test. p&#x000a0;&#x0003c; 0.05 was considered statistically significant. n&#x000a0;= 92 patients.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Multivariate Analysis of Prognostic Parameters in Patients with CRC by Cox Regression Analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Category</th><th>p Value</th></tr></thead><tbody><tr><td>Age (years)</td><td/><td/></tr><tr><td/><td>&#x0003c;60</td><td>0.498</td></tr><tr><td/><td>&#x02265;60</td><td/></tr><tr><td>Sex</td><td/><td/></tr><tr><td/><td>male</td><td>0.333</td></tr><tr><td/><td>female</td><td/></tr><tr><td>Tumor size (cm)</td><td/><td/></tr><tr><td/><td>&#x02264;5</td><td>0.197</td></tr><tr><td/><td>&#x0003e;5</td><td/></tr><tr><td>TNM stage</td><td/><td/></tr><tr><td/><td>I&#x02013;II</td><td>0.032</td></tr><tr><td/><td>III&#x02013;IV</td><td/></tr><tr><td>Lymph node metastasis</td><td/><td/></tr><tr><td/><td>negative</td><td>0.019</td></tr><tr><td/><td>positive</td><td/></tr><tr><td>Distant metastasis</td><td/><td/></tr><tr><td/><td>negative</td><td>0.775</td></tr><tr><td/><td>positive</td><td/></tr><tr><td rowspan="3">LINC01413 level</td><td/><td/></tr><tr><td>low</td><td>0.034</td></tr><tr><td>high</td><td/></tr></tbody></table><table-wrap-foot><fn><p>Proportional hazards method analysis showed a positive, independent prognostic importance of LINC01413 expression (p&#x000a0;= 0.034). p&#x000a0;&#x0003c; 0.05 was considered statistically significant.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec2.2"><title>LINC01413 Regulates Cell Proliferation, Apoptosis, Migration, Invasion, and EMT in CRC Cells</title><p id="p0050">To make sure of the role of LINC01413 in CRC progression, a short hairpin RNA (shRNA) targeting LINC01413 was designed and transfected into LoVo cells, and the cells exhibited a relatively low level of LINC01413 (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A, left). Meanwhile, LINC01413 was overexpressed in HT29 cells after transfecting with pGIPZ/LINC01413 (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A, right). The 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide (MTT) assay results indicated that silencing LINC01413 remarkably inhibited cell viability compared with the negative control shRNA group in LoVo cells, whereas overexpression of LINC01413 in HT29 cells exhibited an opposite effect (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B). In comparison with the negative controls, knockdown of LINC01413 increased the&#x000a0;proportion of apoptotic cells, whereas overexpression of LINC01413 apparently hampered cell apoptosis (<xref rid="fig2" ref-type="fig">Figures 2</xref>C and 2D). In other words, LINC01413 promotes CRC cell growth <italic>in&#x000a0;vitro</italic>.<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>LINC01413 Regulates Cell Proliferation, Apoptosis, Migration, Invasion, and EMT in CRC Cells</p><p>(A) LoVo cells transfected with shLINC01413 show a relatively low level of LINC01413 (left), and HT-29 cells transfected with pGIPZ/LINC01413 exhibit a relatively high expression of LINC01413 (right). (B) MTT assay revealed that knockdown of LINC01413 inhibits cell survival, whereas overexpression of LINC01413 enhances cell survival, compared to the control groups. (C and D) Flow cytometry analysis was used to determine the apoptosis rate of LoVo (C) or HT-29 (D) cells after transfection. (E-H) Transwell assays demonstrated that cells with higher level of LINC01413 with the higher migratory and invasive ability compared with cells with lower level of LINC01413. (I) Immunofluorescence staining indicates that the dysregulation of LINC01413 affects the distribution of E-cadherin and N-cadherin in CRC cells. (J and K) The expression levels of EMT-associated genes in transfected CRC cells were detected by quantitative real-time PCR. (L) Western blot assays were performed to detect the protein levels of the epithelial and mesenchymal markers in response to LINC01413 inhibition or overexpression. Error bars show the mean&#x000a0;&#x000b1; SD of more than three independent experiments. *p&#x000a0;&#x0003c; 0.05, **p&#x000a0;&#x0003c; 0.01 versus control group.</p></caption><graphic xlink:href="gr2"/></fig></p><p id="p0055">To explore the effect of LINC01413 on tumor metastasis in CRC, a Transwell assay was first employed <italic>in&#x000a0;vitro</italic> to test cell migration and invasion capacities. Compared with the negative control, cell&#x000a0;migratory ability was evidently suppressed after silencing LINC01413 in LoVo cells, and, conversely, it was markedly enhanced in LINC01413-overexpressed HT29 cells (<xref rid="fig2" ref-type="fig">Figures 2</xref>E and 2F). Similarly, the invasion ability of CRC cells was controlled along with LINC01413 knockdown while being strengthened along with overexpression, just as for the same trend of cell migratory ability (<xref rid="fig2" ref-type="fig">Figures 2</xref>G and 2H). Furthermore, we assessed whether LINC01413 influences EMT, a hallmark of metastasis in CRC. The immunofluorescence (IF) staining showed that LINC01413 inhibition increased the expression of E-cadherin but decreased that of Vimentin, while LINC01413 upregulation diminished Vimentin expression but improved E-cadherin level (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>I). Furthermore, silencing LINC01413 caused an increased expression of epithelial markers, including E-cadherin and &#x003b2;-catenin, whereas it decreased the levels of mesenchymal markers such as Vimentin and N-cadherin in LoVo cells; however, overexpression of LINC01413 showed an inverse impact on the expression of these genes (<xref rid="fig2" ref-type="fig">Figures 2</xref>J and 2K). Consistently, the results of western blots further justified the observations above (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>L). These investigations reveal that LINC01413 contributes to tumor metastasis of&#x000a0;CRC.</p></sec><sec id="sec2.3"><title>LINC01413 Knockdown Blocks Tumorigenesis and Tumor Metastasis of CRC <italic>In&#x000a0;Vivo</italic></title><p id="p0060">To further validate the promoting role of LINC01413 in CRC cell growth and metastasis, LINC01413-silenced LoVo cells were injected into nude mice while the shCtrl-transfected LoVo cells acted as the control. Consequently, the <italic>in&#x000a0;vivo</italic> xenograft experiments demonstrated that tumors originating from shLINC01413-transfected cells are remarkably smaller than those from control cells (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A). As shown in <xref rid="fig3" ref-type="fig">Figures 3</xref>B and 3C, obvious reductions of tumor volume and weight were found in tumors derived from cells with LINC01413 silencing compared to those from controls. Moreover, the <italic>in&#x000a0;vivo</italic> metastasis assays represented that LINC01413 inhibition markedly lessened the metastatic tumors secondary to the lung when compared to the lungs of control mice (<xref rid="fig3" ref-type="fig">Figures 3</xref>D and 3E). Moreover, silenced LINC01413 significantly increased E-cadherin expression but decreased N-cadherin expression, and the level of ZEB1 protein, which plays a key part in EMT, was also confined under LINC01413 depletion (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>F). Altogether, we illustrated that LINC01413 serves an oncogenic and metastasis-promoting role <italic>in&#x000a0;vivo</italic>.<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>LINC01413 Regulates Tumorigenesis and Tumor Metastasis of CRC <italic>In&#x000a0;Vivo</italic></p><p>(A) Images of tumors formed from shCtrl or shLINC01413-transfected LoVo cells. (B and C) shLINC01413 transfection decreased the volume tumor (B) and weight (C) <italic>in&#x000a0;vivo</italic>. (D-E) Number of metastasis nodules in shLINC01413 group was more than shCtrl group. (F) Western blot reveals that the level of E-cadherin is remarkably increased while the level of ZEB1 and N-cadherin is decreased in tumors originating from LINC01413-silenced LoVo cells when compared to tumors from shCtrl-transfected cells. Error bars show the mean&#x000a0;&#x000b1; SD of more than three independent experiments. **p&#x000a0;&#x0003c; 0.01 versus control group.</p></caption><graphic xlink:href="gr3"/></fig></p></sec><sec id="sec2.4"><title>LINC01413 Modulates ZEB1 Expression through Promoting YAP1/TAZ1 Complex Translocation into Nucleus</title><p id="p0065">To probe the underlying pathway involved in the function of LINC01413 on CRC progression, we first screened the mRNA differential expression profiles of LoVo and HCT-116 cell lines before and after LINC01413 interference by high-throughput microarray technology. It was found that a total of 673 mRNAs were dysregulated (fold change &#x02265;2.0), among which 214 were upregulated and 459 were downregulated (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>). Then, the results from Gene Ontology (GO) and pathway analysis revealed that LINC01413 function is mainly related to the Hippo signaling pathway and cell migration (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S2</xref>). Then, the Pearson correlation coefficient between LINC01413 and other differentially encoded genes was calculated and we found that LINC01413 was significantly correlated with ZEB1, which can initiate EMT. Therefore, we hypothesized a regulatory relationship between LINC01413, ZEB1, and the Hippo signaling pathway during formation of the malignant phenotype in CRC.</p><p id="p0070">To validate this hypothesis, we first examined whether LINC01413 regulates the expression of ZEB1, YAP1, and TAZ1 by quantitative real-time PCR and western blot analysis. As shown in <xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>A, ZEB1 expression declined significantly, whereas the expression of YAP1 and TAZ1 barely changed with the knockdown of LINC01413 in LoVo cells. However, overexpression of LINC01413 upregulated ZEB1, whereas it failed to alter the expression of YAP1 and TAZ1 (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>B). Next, the western blot results showed that the protein levels of ZEB1, YAP1, and TAZ1 changed in the same trend as mRNA levels, except that the phosphorylation levels of YAP1 (at site Ser<sup>127</sup>) and TAZ1 (at site Ser<sup>89</sup>) were greatly upregulated in LINC01413-silenced LoVo cells but downregulated in response to LINC01413 overexpression (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>C). These findings implied that LINC01413 hinders YAP/TAZ phosphorylation so as to inactivate Hippo pathway.<fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>LINC01413 Modulates ZEB1 Expression through Promoting YAP1/TAZ1 Complex Translocation into Nucleus</p><p>(A and B) The expressions of LINC01413, ZEB1, YAP1, and TAZ1 in LoVo cells transfected with shLINC01413 or shCtrl (A) and in HT-29 cells transfected with pGIPZ/LINC01413 or pGIPZ/control (B) were detected by quantitative real-time PCR. (C) The protein levels of ZEB1, YAP1, and TAZ1 in LoVo and HT-29 cells after transfection were estimated by western blot assay. (D and E) Western blot results of the expression of TAZ1 and YAP1 in cytoplasm or nucleus of LoVo (D) and HT-29 (E) cells after silencing or overexpressing LINC01413, respectively. (F) Quantitative real-time PCR analysis of ZEB1 expression in CRC tissues and adjacent non-tumor tissues. (G) Spearman&#x02019;s correlation analysis suggests a positive correlation between ZEB1 expression and LINC01413 in CRC tissues. (H) The binding site of TEAD4 in the region of ZEB1 promoter was predicted by JASPAR. (I) ChIP assay proves that TEAD4, YAP1, and TAZ1 all bind to the ZEB1 promoter. (J and K) Luciferase reporter assays were performed to evaluate the function of YAP1/TAZ1 (J) or LINC01413 (K) in ZEB1 transcription. Error bars show the mean&#x000a0;&#x000b1; SD of more than three independent experiments. **p&#x000a0;&#x0003c; 0.01 versus control group.</p></caption><graphic xlink:href="gr4"/></fig></p><p id="p0075">As is well known, the YAP/TAZ complex has been revealed to exert its carcinogenic function in cancers through the transcriptional activation of target genes in the nucleus. Therefore, we detected the level of YAP1 and TAZ1 in the cytoplasm and nucleus using western blot assay. As a consequence, YAP1 and TAZ1 were found to be highly expressed in cytoplasm and expressed at low levels in nucleus in LINC01413-silenced LoVo cells, whereas they were expressed at low levels in cytoplasm and highly expressed in nucleus in LINC01413-overexpressed HT-29 cells, which indicated that LINC01413 affects the intranuclear and extranuclear distribution of YAP1 and TAZ1 (<xref rid="fig4" ref-type="fig">Figures 4</xref>D and 4E). Furthermore, we also discovered that ZEB1, an EMT activator that has been reported as a target of YAP/TAZ,<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> was remarkably upregulated in CRC tissues and was positively correlated with LINC01413 in 92 CRC tissues (<xref rid="fig4" ref-type="fig">Figures 4</xref>F and 4G). Moreover, the UCSC genome browser suggested that TEAD4 is a possible transcription factor regulating ZEB1 transcription (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>A). According to the TEAD4-binding motif obtained from JASPAR (<ext-link ext-link-type="uri" xlink:href="http://jaspar.genereg.net/" id="intref0010">http://jaspar.genereg.net/</ext-link>) (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>B), we discovered that TEAD4 is most likely to bind to the ZEB1 promoter at the &#x02212;1245 to &#x02212;1250 site upstream of the transcriptional start site (TSS) (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>H). Furthermore, we observed that the ZEB1 promoter is highly enriched by anti-TEAD4, anti-YAP1, and anti-TAZ1 (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>I). Also, we suggest that the luciferase activity of the&#x000a0;ZEB1 promoter was clearly enhanced under YAP1 and TAZ1 overexpression or LINC01413 upregulation, but it was reduced under LINC01413 inhibition (<xref rid="fig4" ref-type="fig">Figures 4</xref>J and 4K), proving that LINC01413 reinforces ZEB1 transcription via a YAP/TAZ-mediated manner. Additionally, it seems that LINC01413 also influences the transcription of CYR61 and CTGF, two well-known targets downstream YAP/TAZ, because we observed that LINC01413 depletion decreased the binding of YAP/TAZ to their promoters and consequently resulted in the decline of luciferase activities of their promoters (<xref rid="mmc1" ref-type="supplementary-material">Figures S4</xref>A and S4B). These findings suggest that LINC01413 upregulates ZEB1 expression in CRC cells through enhancing the transcriptional activity of the YAP1/TAZ1 complex.</p></sec><sec id="sec2.5"><title>LINC01413 Stimulates Nuclear Translocation of the YAP1/TAZ1 Complex by Binding with hnRNP-K</title><p id="p0080">Recently, many reports have revealed that lncRNAs can regulate gene expression through interacting with proteins. Thus, we suspected that LINC01413 may have an impact on YAP/TAZ in such a way. Through an RNA pull-down assay and mass spectrometry, we found that there are 27 proteins interacting with LINC01413, among which hnRNP-K showed the highest binding score (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A; <xref rid="tbl3" ref-type="table">Table 3</xref>), and the interactivity of LINC01413 with hnRNP-K was further confirmed by RNA pull-down and an RNA immunoprecipitation (RIP) assay (<xref rid="fig5" ref-type="fig">Figures 5</xref>B and 5C). Through prediction by the online tool RNA-Protein Interaction Prediction (RPISeq) (<ext-link ext-link-type="uri" xlink:href="http://pridb.gdcb.iastate.edu/RPISeq/" id="intref0015">http://pridb.gdcb.iastate.edu/RPISeq/</ext-link>), we found that LINC01413 has a high potential to bind with hnRNP-K at 0&#x02013;198&#x000a0;bp upstream of the 3&#x02032; end of LINC01413 (shown in red in <xref rid="tbox1" ref-type="boxed-text">Box 1</xref>), among which the sequence at 67&#x02013;98&#x000a0;bp upstream of the 3&#x02032; end of LINC01413 (further highlighted in yellow in <xref rid="tbox1" ref-type="boxed-text">Box 1</xref>) maintains the highest conservatism and the highest binding potential (<xref rid="tbox1" ref-type="boxed-text">Box 1</xref>). More importantly, it exhibited that hnRNP-K no longer interacts with LINC01413 when the sequence 67&#x02013;98&#x000a0;bp upstream of the 3&#x02032; end of LINC01413 mutated (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>D). Moreover, the fluorescence <italic>in situ</italic> hybridization (FISH) results represented that both LINC01413 and hnRNP-K are expressed not only in the nucleus but also in the cytoplasm, and, more importantly, the co-localization of these two genes was also displayed here (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>E). These data reveal the direct interaction between LINC01413 and hnRNP-K in CRC cells.<fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>LINC01413 Stimulates ZEB1 Expression and the Nuclear Translocation of the YAP1/TAZ1 Complex by Binding with hnRNP-k</p><p>(A) A western blot assay after a RNA pull-down assay was applied to test protein interaction with LINC01413. (B) RNA pull-down showed the enrichment of hnRNP-k in response to LINC01413 compared with negative control IgG. (C) RIP assay detected the enrichment of LINC01413 in anti-hnRNP-k group compared with anti-IgG. (D) The specific interaction between LINC01413 and hnRNP-K was confirmed by an RNA pull-down&#x000a0;assay. (E) The locations of LINC01413 and hnRNP-K in LoVo cells were assessed using FISH. (F) The cross-talk among LINC01413, hnRNP-K, YAP1, and TAZ1 in CRC cells was identified via a coIP assay. (G and H) The impact of the LINC01413/hnRNP-K axis on the nuclear translocation of YAP and TAZ was assessed by IF staining (G) and subcellular fractionation followed by western blot analysis (H). Error bars show the mean&#x000a0;&#x000b1; SD of more than three independent experiments. **p&#x000a0;&#x0003c; 0.001 versus control&#x000a0;group.</p></caption><graphic xlink:href="gr5"/></fig><table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>The Potential Chaperonins for LINC01413</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Protein</th><th>Score</th><th>Mass</th><th>Matches</th><th>Sequences</th></tr></thead><tbody><tr><td align="right">1</td><td>hnRNP-K_HUMAN</td><td align="right">998</td><td align="right">224,394</td><td>181 (62)</td><td>106 (44)</td></tr><tr><td align="right">2</td><td>Q8WZ42_HUMAN</td><td align="right">861</td><td align="right">3,842,904</td><td>261 (68)</td><td>244 (67)</td></tr><tr><td align="right">3</td><td>P16615_HUMAN</td><td align="right">321</td><td align="right">116,336</td><td>43 (20)</td><td>33 (16)</td></tr><tr><td align="right">4</td><td>P25705_HUMAN</td><td align="right">307</td><td align="right">59,828</td><td>37 (15)</td><td>24 (13)</td></tr><tr><td align="right">5</td><td>P63261_HUMAN</td><td align="right">232</td><td align="right">42,108</td><td>32 (12)</td><td>16 (9)</td></tr><tr><td align="right">6</td><td>P35609_HUMAN</td><td align="right">217</td><td align="right">104,358</td><td>42 (12)</td><td>33 (12)</td></tr><tr><td align="right">7</td><td>P10809_HUMAN</td><td align="right">200</td><td align="right">61,187</td><td>12 (6)</td><td>12 (6)</td></tr><tr><td align="right">8</td><td>Q00839_HUMAN</td><td align="right">194</td><td align="right">91,269</td><td>45 (14)</td><td>23 (11)</td></tr><tr><td align="right">9</td><td>E9PKE3_HUMAN</td><td align="right">171</td><td align="right">68,991</td><td>24 (9)</td><td>17 (8)</td></tr><tr><td align="right">10</td><td>A8MXZ9_HUMAN</td><td align="right">171</td><td align="right">141,774</td><td>18 (9)</td><td>14 (7)</td></tr><tr><td align="right">11</td><td>Q12906_HUMAN</td><td align="right">166</td><td align="right">95,678</td><td>35 (12)</td><td>21 (9)</td></tr><tr><td align="right">12</td><td>Q08211_HUMAN</td><td align="right">161</td><td align="right">142,181</td><td>33 (14)</td><td>21 (11)</td></tr><tr><td align="right">13</td><td>B4DFL2_HUMAN</td><td align="right">152</td><td align="right">45,550</td><td>18 (8)</td><td>11 (7)</td></tr><tr><td align="right">14</td><td>P06576_HUMAN</td><td align="right">146</td><td align="right">56,525</td><td>35 (10)</td><td>17 (8)</td></tr><tr><td align="right">15</td><td>P09493_HUMAN</td><td align="right">144</td><td align="right">32,746</td><td>41 (9)</td><td>31 (7)</td></tr><tr><td align="right">16</td><td>P06732_HUMAN</td><td align="right">136</td><td align="right">43,302</td><td>17 (6)</td><td>13 (6)</td></tr><tr><td align="right">17</td><td>Q01082_HUMAN</td><td align="right">131</td><td align="right">275,237</td><td>16 (5)</td><td>14 (5)</td></tr><tr><td align="right">18</td><td>P18206_HUMAN</td><td align="right">131</td><td align="right">124,292</td><td>20 (8)</td><td>20 (8)</td></tr><tr><td align="right">19</td><td>P38646_HUMAN</td><td align="right">126</td><td align="right">73,920</td><td>24 (5)</td><td>21 (5)</td></tr><tr><td align="right">20</td><td>P00505_HUMAN</td><td align="right">114</td><td align="right">47,886</td><td>17 (5)</td><td>13 (4)</td></tr><tr><td align="right">21</td><td>A8MX12_HUMAN</td><td align="right">114</td><td align="right">189,126</td><td>13 (6)</td><td>12 (6)</td></tr><tr><td align="right">22</td><td>Q9UJS0_HUMAN</td><td align="right">111</td><td align="right">74,528</td><td>9 (6)</td><td>8 (5)</td></tr><tr><td align="right">23</td><td>C9JW96_HUMAN</td><td align="right">108</td><td align="right">26,932</td><td>9 (5)</td><td>7 (5)</td></tr><tr><td align="right">24</td><td>Q13423_HUMAN</td><td align="right">108</td><td align="right">114,564</td><td>18 (5)</td><td>15 (5)</td></tr><tr><td align="right">25</td><td>P17540_HUMAN</td><td align="right">107</td><td align="right">47,988</td><td>11 (3)</td><td>7 (3)</td></tr><tr><td align="right">26</td><td>A2A274_HUMAN</td><td align="right">106</td><td align="right">88,563</td><td>27 (5)</td><td>18 (4)</td></tr><tr><td align="right">27</td><td>P16219_HUMAN</td><td align="right">99</td><td align="right">44,611</td><td>7 (2)</td><td>4 (2)</td></tr></tbody></table><table-wrap-foot><fn><p>These chaperonins were screened out using RNA immunoprecipitation and mass spectrometry.</p></fn></table-wrap-foot></table-wrap><boxed-text id="tbox1"><label>Box 1</label><caption><title>Sequences in LINC01413 for the Binding of hnRNP-K</title></caption><p id="p0390"><table-wrap position="float" id="undtbl1"><table frame="hsides" rules="groups"><thead><tr><th>Homo sapiens long intergenic non-protein coding RNA 1413 (LINC01413):</th></tr></thead><tbody><tr><td>CGGTACTGAGAGCAGCCATCTTGGAGCTTGGAAACGGAGACGC<break/>ATGTGAAGCCGTTTGCACAGTATTTTTCCCTTAAAATATGGGTG<break/>GGGAACAAGGGGCTGTCATTTGTCTTTTTCTTTGGGATGGTGAGC<break/>AGTGAGCAGGGCACGCCGCGAGGAGCAAACTGCAGCCCAAGC<break/>ACACGCGGTCAGCACGCGGAGCACAGGTGGGGAGAAGCGGCT<break/>GACGGTGGCGTGGCCCCGCGTACCTGGGTGTGGACGCCCCGCC<break/>GCCCCGCAGGGGAAAGCTCCTGGAGTCTGGGGTCTGCTGCCCC<break/>GAGCTCTGGGTGTCCAGCCTCTGCCTCAACTGAAATCTGAAGA<break/>TCAGGCCAATTTCGTGGTCTCTCAGACGTCGGTAAACAAGAGGC<break/>CTTGGCTCCTCAGGAGACCGAGAGTCTCTCACTGTACTTCCTTC<break/>TCTTGGCTCCAAGGACATAGAACGGTTGCTATGGGGATTCCTT<break/>CATTTGTAAAGACAATCATGCTGGCTGTTAGTGAAGAATGGCC<break/>TGGAGCACTGGGTCTCCGCCCCAGCTGCCTGGGAGAAACTGT<break/>GTTGAAGGAGCCATACCCCCTGGCCTCCCCTCCAGACTCCAGA<break/>CAACCCCAGTCAGCTGGCTGGGAGGGAGGCAGAAGAGAAACA<break/>GGGGTGCACCTGGGGCTCCTGCAGGGGTCCAGCCAGGAGATG<break/>GGGGCAACTTGGACAGGGACGATCCTGGGAAGGGCAGGAGG<break/>AGGAGTGAGACCTGGCCTGCCCTCTCCCTAGAGGCTCATCAGC<break/>TCCCTGGAGACAGACACGCCCTGGTTCCTTTCCCTATGCCTGG<break/>AGCCTGGGTACCAGCTATTGAAAACTGCTTTTCTCCTTGTTCAT<break/>TCAAACATATTCACACATAAAGGTTGTCATTCCTTTTTGTCACT<break/>ATTTGACAAAAATTGGATCATACCGTATACAATTCTCTGCTATT<break/>TGTTTTGCTCACCTAACAATAAATACACTGTGAAAAATA</td></tr></tbody></table><table-wrap-foot><fn><p>RPISeq predicted that hnRNP-K might bind with LINC01413 at 0&#x02013;198&#x000a0;bp upstream of the 3&#x02032; end of LINC01413 (shown in red), with the sequence of 67&#x02013;98&#x000a0;bp upstream of the 3&#x02032; end of LINC01413 (highlighted in yellow) maintaining the highest conservatism and the highest binding potential.</p></fn></table-wrap-foot></table-wrap></p></boxed-text></p><p id="p0085">To explore whether LINC01413 exerts its effects on CRC via hnRNP-K, the following experiments were conducted. First, we found that altering hnRNP-K expression had no influence on LINC01413 expression (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S4</xref>C). Interestingly, silencing hnRNP-K led to noticeable downregulation of ZEB1, stimulated phosphorylation of YAP1 as well as TAZ1, and blocked their nuclear translocation, with total levels of YAP1 and TAZ1 rarely changed (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S4</xref>D), similar to results observed in LoVo cells upon LINC01413 silencing (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>E). Nevertheless, opposite phenomena were shown in hnRNP-K-overexpressed HT-29 cells (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S4</xref>E). These results highlight that LINC01413 stimulates YAP1/TAZ1 nuclear translocation by relying on hnRNP-K to modulate YAP1/TAZ1/ZEB1 signaling.</p><p id="p0090">Next, we sought to identify the detailed mechanism whereby the LINC01413/hnRNP-K axis affects YAP1/TAZ1 nuclear translocation. Due to the ability of hnRNP-K to interact with a range of molecular partners, including DNA, RNA, and proteins, we speculated that LINC01413 promotes YAP1/TAZ1 nuclear translocation through recruiting hnRNP-K. To verify this speculation, co-immunoprecipitation (coIP) analysis was applied. It was shown that the enriched YAP1, TAZ1, and LINC01413 in the hnRNP-K-precipitated complex were all diminished under LINC01413 depletion, and upregulating hnRNP-K partly recovered the enrichment of only YAP1/TAZ1. In contrast, ectopic LINC01413 remarkably boosted YAP1/TAZ1/LINC01413 in hnRNP-K immunoprecipitates, and sh-hnRNP-K co-transfection normalized YAP1/TAZ1 enrichment (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>F). Furthermore, hnRNP-K stimulation reversed the accumulation of cytoplasmic YAP1/TAZ1 and decreased nuclear YAP1/TAZ1 caused by LINC01413 silencing, whereas hnRNP-K inhibition offset the stimulatory impact of forced LINC01413 expression on YAP1/TAZ1 nuclear translocation (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>G). Such phenomena were further confirmed by western blot analyses (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>H). Taken together, LINC01413 promotes YAP1/TAZ1 translocation into nucleus via an hnRNP-K-dependent manner.</p></sec><sec id="sec2.6"><title>The LINC01413/hnRNP-K/TAZ1/YAP1/ZEB1 Axis Stimulates Formation of a Malignant Phenotype in CRC</title><p id="p0095">Subsequently, we attempted to verify whether LINC01413 functions in CRC through modulating the hnRNP-K/TAZ1/YAP1/ZEB1 axis. First, the effect of hnRNP-K on LINC01413-affected YAP1/TAZ1/ZEB1 signaling was estimated. As displayed in <xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>A, overexpression of hnRNP-K neutralized the decrease of ZEB1 levels and the increase of p-YAP1 and p-TAZ1 levels in LINC01413-silenced LoVo cells. Accordingly, its knockdown reversed the increase of ZEB1 expression as well as the decrease of the phosphorylation levels of YAP1 and TAZ1 in HT-29 cells in the context of LINC01413 overexpression. Moreover, overexpressed hnRNP-K impaired the impact of shLINC01413 on reducing nuclear harvest of YAP1/TAZ1 and stimulating cytoplasmic accumulation of YAP1/TAZ1 in LoVo cells, whereas hnRNP-K silence manifested an opposite effect on the distribution of YAP1/TAZ1 in LINC01413-upregulated HT-29 cells (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>B), revealing that the translocation of YAP1/TAZ1 is regulated by the LINC01413/hnRNP-K axis.<fig id="fig6"><label>Figure&#x000a0;6</label><caption><p>LINC01413/hnRNP-K/TAZ1/YAP1/ZEB1 Axis Stimulates the Formation of a Malignant Phenotype in CRC</p><p>(A and B) Western blot analysis reveals that LINC01413 affects the expression of ZEB1, YAP1, and TAZ1 (A) as well as the distribution of YAP1 and TAZ1 (B) via an hnRNP-K-dependent pathway. (C-D) MTT assay and flow cytometry analysis showed the cell viability and apoptosis in LINC01413-downregulated -upregulated cells were recovered after overexpression or knockdown of hnRNP-k. (E and F) The migration (E) and invasion (F) capacities of cells under different conditions were evaluated by a Transwell assay. (G) Western blot analysis determines the levels of proteins involved in EMT in CRC cells facing diverse situations. Error bars show the mean&#x000a0;&#x000b1; SD of more than three independent experiments. **p&#x000a0;&#x0003c; 0.01 versus control group.</p></caption><graphic xlink:href="gr6"/></fig></p><p id="p0100">Thereafter, we further investigated regulation of the LINC01413/hnRNP-K axis on the biological behaviors of CRC cells. As shown in <xref rid="fig6" ref-type="fig">Figures 6</xref>C and CD, cell viability and apoptosis influenced by LINC01413 inhibition or overexpression were reversed in response to hnRNP-K upregulation or downregulation, respectively. Results of the Transwell assay revealed that co-transfection of pGIPZ/hnRNP-K recovered cell migration and invasion abilities of LoVo cells, which were confined by LINC01413 inhibition, and hnRNP-K silencing led to opposite results (<xref rid="fig6" ref-type="fig">Figures 6</xref>E and 6F). Additionally, the impact of LINC01413 silencing or enhancement on EMT process in CRC cells was counteracted by hnRNP-K overexpression or depletion, respectively (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>G). Importantly, we found that expression of ZEB1 declined at both mRNA and protein levels, but levels of p-YAP1 (Ser<sup>127</sup>) and p-TAZ1 (Ser<sup>89</sup>) were augmented (with the mRNA and protein levels of YAP1 and TAZ1 being unaffected) in <italic>in&#x000a0;vivo</italic> tumors in the context of LINC01413 knockdown (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S4</xref>F). In conclusion, these observations prove that LINC01413 promotes tumorigenesis and metastasis in CRC through modulating the hnRNP-K/TAZ1/YAP1/ZEB1 axis.</p><p id="p0105">In summary, our study provides the first evidence that LINC01413 contributes to CRC tumorigenesis and development by recruiting hnRNP-K to promote nuclear translocation of YAP1/TAZ1 so as to inspire ZEB1 expression, thus enhancing EMT and metastasis in CRC (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>).<fig id="fig7"><label>Figure&#x000a0;7</label><caption><p>LINC01413 Promotes Nuclear Translocation of YAP1/TAZ1 by Recruiting hnRNP-K and Then Stimulates ZEB1 Expression, Thus Enhancing EMT and Metastasis in CRC</p></caption><graphic xlink:href="gr7"/></fig></p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0110">CRC is one of the most frequent human cancers in the world and occupies fourth place in the ranking of the primary causes of cancer-associated death.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> Upon most occasions, CRC cases are divided into four stages according to clinical symptoms, and an advanced stage usually leads to poor prognosis.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> In the past decade, lncRNAs have been identified to be as important in cell biology as are miRNAs.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> The dysregulation of lncRNAs has been suggested to be associated with a number of human diseases, cancer included.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref> For example, the lncRNA UICLM accelerates CRC liver metastasis by functioning as a competing endogenous RNA (ceRNA) of ZEB2 via sponging miR-215.<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> In the present study, we reveal a novel lncRNA LINC01413 as a facilitator in human CRC based on its promoting role in CRC cell growth and metastasis as evidenced by vitro and <italic>in&#x000a0;vivo</italic> experiments.</p><p id="p0115">Tumor metastasis accounts for a large proportion of cancer-caused death, and EMT is regarded as a key step in tumor metastasis because it increases cancer cell motility and invasiveness.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> EMT occurs when epithelial cells differentiate into a mesenchymal phenotype and obtain the abilities of motility and invasion, which are strongly related to metastasis.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> Also, EMT is controlled by a number of factors, among which ZEB1 is a primary factor of the network of transcription factors that activates EMT.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> Additionally, lncRNAs have also been found to play roles in this process.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> For instance, lncRNA NKILA suppresses transforming growth factor &#x003b2; (TGF-&#x003b2;)-induced EMT by blocking nuclear factor &#x003ba;B (NF-&#x003ba;B) signaling in breast cancer.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> In our study, we found that LINC01413 also functions as a positive regulator of EMT in CRC through a ZEB1-mediated way. Also, we show that the impact of LINC01413 on EMT in CRC is closely related to the Hippo pathway, a well-known tumor suppressive pathway.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> Furthermore, we prove that ZEB1 is transcriptionally regulated by YAP/TAZ, which is concordant with the evidence that ZEB1 is a target of YAP/TAZ, as supported by a previous report.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref></p><p id="p0120">hnRNP-K, belonging to the heterogeneous nuclear ribonucleoproteins (hnRNPs) family, is a kind of RNA-binding protein (RBP) that is of great importance in post-transcriptional events, in which lncRNAs are usually implicated.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> In addition, aberrant hnRNP-K expression usually leads to tumorigenesis.<xref rid="bib42" ref-type="bibr">42</xref>, <xref rid="bib43" ref-type="bibr">43</xref>, <xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref> For example, hnRNP-K is a haplo-insufficient tumor suppressor that regulates proliferation and differentiation programs in hematologic malignancies.<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> Furthermore, hnRNP-K has been reported to function in various cellular processes, such as transcription, mRNA splicing to translation, as well as chromatin remodeling,<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref> and such a role of hnRNP-K has been shown to be associated with its diverse interaction with RNA, DNA, and proteins.<xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> Currently, we observed the interactivity of hnRNP-K not only with LINC01413, but also with the YAP1/TAZ1 complex, which is the key protein in Hippo signaling, revealing the cross-talk among LINC01413, hnRNP-K, YAP1, and TAZ1 in CRC cells. Recently, studies have revealed that lncRNAs can obstruct YAP phosphorylation by interacting with YAP protein through direct or indirect manners. For instance, lncARSR directly interacts with YAP to prevent LATS1-induced YAP phosphorylation.<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> lncRNA B4GALT1&#x02010;AS1 enhances YAP transcriptional activity in colon cancer by interacting with YAP and inducing its nuclear translocation.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> Also, Lin et&#x000a0;al.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> reported that a UCA1/AMOT/YAP interaction complex contributes to YAP dephosphorylation and nuclear translocation. Herein, we discovered that the LINC01413/hnRNP-K/YAP1/TAZ1 complex hinders YAP1 and TAZ1 phosphorylation to block their degradation, resulting in enhanced nuclear translocation of YAP1 and TAZ1 in CRC cells. On this basis, LINC01413 boosts ZEB1 transcription in CRC cells. Herein, we found that the accelerating role of LINC01413 in CRC cell growth and metastasis is mediated by ZEB1 through LINC01413/hnRNP-K/YAP1/TAZ1 signaling.</p><p id="p0125">All in all, the current study primarily elaborates that the LINC01413/hnRNP-K/YAP1/TAZ1/ZEB1 axis promotes CRC progression, especially EMT-accelerated metastasis. Our findings identify LINC01413 as a novel potential prognostic and therapeutic target in CRC, exploiting a new path for the treatment of CRC patients, although there is still a long way to go until its eventual application.</p></sec><sec id="sec4"><title>Materials and Methods</title><sec id="sec4.1"><title>Microarray Analysis</title><p id="p0130">For lncRNA analysis, three CRC tissues and corresponding non-tumor tissues were used for the microarray detection of lncRNAs. These patients had neither other underlying diseases, such as diabetes or hypertension, nor the reception of any other treatments prior to surgery. lncRNA microarray detection (H1602063, Arraystar_-Human_LncRNA_8x60k v3.0 1-color) was carried out and analyzed by Shanghai Bohao Biotechnology (Shanghai, China), and a total of 473 lncRNAs were found to be differentially expressed between tumor and non-tumor tissues, with 43 being changed 14-fold or more, among which 26 were upregulated and 17 were downregulated.</p><p id="p0135">For mRNA analysis, extracted RNA was transcribed and amplified into fluorescent cRNA after removing the rRNA (mRNA-ONLY eukaryotic mRNA isolation kit, Epicenter Biotechnologies, Madison, WI, USA). Then, cRNAs were tagged and hybridized onto the Human MRNA Array v3.0 (8&#x000a0;&#x000d7; 60 K, Arraystar, Rockville, MD, USA). The arrays were scanned by the Agilent G2505C scanner after washing, and the array images acquired were analyzed by the Agilent Feature Extraction software (version 11.0.1.1). The GeneSpring GX v11.5.1 software package (Agilent Technologies) was used to perform quantile normalization following data processing. Based on fold change filtering, genes with a fold change &#x02265;2.0 or &#x02264;0.5 were identified to be differentially expressed, and the expression profiles were visualized by using the Molecular Signatures Database (MSigDB, <ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/msigdb" id="intref0020">http://www.broadinstitute.org/msigdb</ext-link>). The microarray detection of mRNAs was also performed by Shanghai Bohao Biotechnology (Shanghai, China).</p></sec><sec id="sec4.2"><title>GO Analysis and Pathway Analysis</title><p id="p0140">GO and pathway analyses were conducted as described<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> to better understand the roles of these differentially expressed genes. In this process, three independent categories, including biological process (BP), cellular component (CC), and molecular function (MF), were&#x000a0;all derived from the GO Consortium website (<ext-link ext-link-type="uri" xlink:href="http://www.geneontology.org" id="intref0025">http://www.geneontology.org</ext-link>).<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> The Database for Annotation, Visualization and Integrated Discovery (DAVID, <ext-link ext-link-type="uri" xlink:href="http://david.abcc.ncifcrf.gov/" id="intref0030">http://david.abcc.ncifcrf.gov/</ext-link>) was applied to assess the changes of the upregulated and downregulated genes. The biological pathways with obvious enriched genes that&#x000a0;were differentially expressed were analyzed by the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (<ext-link ext-link-type="uri" xlink:href="http://www.genome.jp/kegg/" id="intref0035">http://www.genome.jp/kegg/</ext-link>).</p></sec><sec id="sec4.3"><title>Tissue Specimens</title><p id="p0145">A total of 92 pairs of tumor and adjacent non-tumor tissues were used in this study. These tissue specimens were obtained from CRC patients who underwent surgical operations in The First Hospital of Wenzhou Medical University. None of the patients suffered from chemotherapy or radiotherapy prior to surgery. This study was approved by the Ethics Committee of The First Hospital of Wenzhou Medical University (with the ethical approval no. YS2019-373). All patients signed the personal informed consent.</p></sec><sec id="sec4.4"><title>Cell Culture</title><p id="p0150">The normal human colon epithelial cell line (NCM460) and five CRC cell lines (SW480, SW620, HCT-116, HT-29, and LoVo) were obtained from the American Type Culture Collection (Manassas, VA, USA). All cells were cultured in Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM; Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Wisent, Ottawa, ON, Canada), 100&#x000a0;U/mL penicillin, and 100&#x000a0;mg/mL streptomycin (Invitrogen), and the cells were kept under humid condition at 37&#x000b0;C with 5%&#x000a0;CO<sub>2</sub>.</p></sec><sec id="sec4.5"><title>Cell Transfection</title><p id="p0155">Cells were inoculated in six-well plates at a concentration of 2&#x000a0;&#x000d7; 10<sup>5</sup> per well and maintained at 37&#x000b0;C in an incubator overnight. The silencing or overexpressing recombinant plasmids (shLINC01413 and shCtrl; pGIPZ/LINC01413 and pGIPZ/control; sh-hnRNP-K and shCtrl; pGIPZ/hnRNP-K and pGIPZ/control) were all constructed via pSUPER-EGFP1 vector. Thereafter, the plasmids were transfected into indicated cells as required by using Lipofectamine 2000 (Invitrogen), and the stably transfected ones were selected using G418 (Clontech, CA, USA). These stable cells were collected and kept for future use.</p></sec><sec id="sec4.6"><title>RNA Isolation and Quantitative Real-Time PCR</title><p id="p0160">TRIzol reagent (Invitrogen) was used to extract total RNA from tissues and cells. NanoDrop 2000c (Thermo Scientific, Waltham, MA, USA) was applied to determine the RNA concentration and quality. After that, a reverse transcription kit (Takara, Tokyo, Japan) was used to transcribe the RNA reversely into cDNA, and quantitative real-time PCR was evaluated using SYBR Green (Takara). GAPDH was used as the normalized control. The primers used for quantitative real-time PCR are as follows:</p><p id="p0165">LINC01413<list list-type="simple" id="ulist0010"><list-item id="u0010"><p id="p0170">Forward: 5&#x02032;-AGG CAC CTA GCC TAA CAG GA-3&#x02032;</p></list-item><list-item id="u0015"><p id="p0175">Reverse: 5&#x02032;-GGG CTT CAA CTC CTG ACA CA-3&#x02032;</p></list-item></list></p><p id="p0180">LINC02043<list list-type="simple" id="ulist0015"><list-item id="u0020"><p id="p0185">Forward: 5&#x02032;-GAG GAA CGG AAG AAC GGA GG-3&#x02032;</p></list-item><list-item id="u0025"><p id="p0190">Reverse: 5&#x02032;-GGG CTG GAA CCA GCT AAT CA-3&#x02032;</p></list-item></list></p><p id="p0195">LINC01836<list list-type="simple" id="ulist0020"><list-item id="u0030"><p id="p0200">Forward: 5&#x02032;-AAC ATG GGC ACC TGG GTA TG-3&#x02032;</p></list-item><list-item id="u0035"><p id="p0205">Reverse: 5&#x02032;-TAG AAT CCG TTG GGC CAC TG-3&#x02032;</p></list-item></list></p><p id="p0210">MIR4713<list list-type="simple" id="ulist0025"><list-item id="u0040"><p id="p0215">Forward: 5&#x02032;-GGG CTC TAA CCT CAG GTG TT-3&#x02032;</p></list-item><list-item id="u0045"><p id="p0220">Reverse: 5&#x02032;-ACC CCA CAA TTG CAG TGA CA-3&#x02032;</p></list-item></list></p><p id="p0225">LRP1-AS<list list-type="simple" id="ulist0030"><list-item id="u0050"><p id="p0230">Forward: 5&#x02032;-GGG TGA CAG CCA GAC ATT CA-3&#x02032;</p></list-item><list-item id="u0055"><p id="p0235">Reverse: 5&#x02032;-TGC CAT ACA GTG GGC TTC TG-3&#x02032;</p></list-item></list></p><p id="p0240">ZEB1<list list-type="simple" id="ulist0035"><list-item id="u0060"><p id="p0245">Forward: 5&#x02032;-AAG TGG CGG TAG ATG GTA ATG T-3&#x02032;</p></list-item><list-item id="u0065"><p id="p0250">Reverse: 5&#x02032;-AAG GAA GAC TGA TGG CTG AAA T-3&#x02032;</p></list-item></list></p><p id="p0255">YAP1<list list-type="simple" id="ulist0040"><list-item id="u0070"><p id="p0260">Forward: 5&#x02032;-TAG CCC TGC GTA GCC AGT TA-3&#x02032;</p></list-item><list-item id="u0075"><p id="p0265">Reverse: 5&#x02032;-TCA TGC TTA GTC CAC TGT CTGT-3&#x02032;</p></list-item></list></p><p id="p0270">TAZ1<list list-type="simple" id="ulist0045"><list-item id="u0080"><p id="p0275">Forward: 5&#x02032;-ACT AAT GGT TGA TTA TCA AGA TCT TCA AGT TGG G-3&#x02032;</p></list-item><list-item id="u0085"><p id="p0280">Reverse: 5&#x02032;-ACT ATT AAA TTG GAA AAA ATG TAA AAT ACT GAT GAT CAC GG-3&#x02032;</p></list-item></list></p><p id="p0285">GAPDH<list list-type="simple" id="ulist0050"><list-item id="u0090"><p id="p0290">Forward: 5&#x02032;-GGA AAA GGA CAT TTC CAC CGC-3&#x02032;</p></list-item><list-item id="u0095"><p id="p0295">Reverse: 5&#x02032;-AGG AGT GGG AGC ACA GGT AA-3&#x02032;</p></list-item></list></p></sec><sec id="sec4.7"><title>MTT Assay</title><p id="p0300">An MTT assay was used to determine cell viability. All of the cells were added into 96-well plates at a concentration of 5&#x000a0;&#x000d7; 10<sup>3</sup> cells/well. After a 48-h incubation, 20&#x000a0;&#x003bc;L of MTT (5&#x000a0;mg/mL; Sigma-Aldrich) was added into each well and the cells were then maintained in a humidified incubator. Four hours later, the supernatant was removed and 50&#x000a0;&#x003bc;L of DMSO was added to every well to dissolve the formazan. Then, the cell viability of different treated cells was determined by detecting the absorbance in the wave of 490&#x000a0;nm normalized to non-treated cells.</p></sec><sec id="sec4.8"><title>Cell Apoptosis Analysis</title><p id="p0305">First, cells were placed in Petri dishes (10-cm diameter, 3&#x000a0;&#x000d7; 10<sup>4</sup> cells/dish), and cells in each dish were incubated with 2&#x000a0;&#x003bc;g/mL cisplatin for 48&#x000a0;h after growing to cover 80% of the entire dish. Then, flow cytometry analysis was carried out to evaluate the apoptosis rate of the cells collected from each dish using the annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) staining method (Beyotime, China).</p></sec><sec id="sec4.9"><title>Transwell Assays</title><p id="p0310">For cell migration assays, cells (1&#x000a0;&#x000d7; 10<sup>5</sup>) maintained in the medium without FBS were placed into the upper compartment (Millipore, Billerica, MA, USA), and the medium in the lower compartment was supplemented with 10% FBS, which functions as a chemoattractant. After incubation for 24 h, cells traveling through the pores were fixed and stained with crystal violet. Then, the cells in five random fields were counted with an inverted microscope. For cell invasion assays, all of the steps were the same as for the migration assays except that cells were seeded in the upper Transwell inserts, which had been coated with Matrigel (BD Biosciences, New York, NY, USA) for 30&#x000a0;min at 37&#x000b0;C. All data were obtained from three independent assays.</p></sec><sec id="sec4.10"><title>IF Staining</title><p id="p0315">Cells were placed on coverslips in 24-well plates and then washed with cold PBS three times. Then, the coverslips were fixed with 4% formaldehyde and immunostained using monoclonal antibodies of E-cadherin and Vimentin. After that, DNA of these cells was stained with 4&#x02032;,6-diamidino-2-phenylindole (DAPI). The Alexa Fluor 546 (red) goat anti-rabbit antibody (Molecular Probes, OR, USA) was used for E-cadherin (no. 14472, 1:50; Cell Signaling Technology, Boston, MA, USA) and Vimentin (sc-66002, 1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Immunofluorescence was determined using confocal microscopy (Leica TCS SP5).</p></sec><sec id="sec4.11"><title><italic>In&#x000a0;Vivo</italic> Assays</title><p id="p0320">For <italic>in&#x000a0;vivo</italic> xenograft experiments, a total of eight BALB/C-nu/nu mice with an age of 5&#x000a0;weeks were raised in a specific pathogen-free (SPF) environment with air conditioning. These mice, half males and half females, were randomly divided into two groups (four mice per group), and then LoVo cells (1&#x000a0;&#x000d7; 10<sup>6</sup> cells per mouse) transfected with shLINC01413 or empty vector were inoculated in mice at the left flank, respectively. Then, the tumors grown in two groups were measured every 4&#x000a0;days until mice were sacrificed. After the mice were sacrificed, these tumors were excised, weighed, and photographed. In respect to <italic>in&#x000a0;vivo</italic> metastasis experiments, LINC01413-silenced LoVo cells or the corresponding control cells were injected into the tail veins of mice. After 6&#x000a0;weeks of injection, all of the mice above were euthanized, and all of the tumors were finally paraffin embedded. All animal experiments in our study were approved by the Animal Welfare and Research Ethics Committee at The First Hospital of Wenzhou Medical University and were carried out strictly according to the <italic>Guide for the Care and Use of Laboratory Animals</italic>.</p></sec><sec id="sec4.12"><title>Subcellular Fractionation Location</title><p id="p0325">The PARIS kit (Life Technologies, Carlsbad, CA, USA) was used to separate the nuclear and cytosolic fractions of cells on the basis of the manufacturer&#x02019;s recommendations.</p></sec><sec id="sec4.13"><title>RNA Pull-Down Assay</title><p id="p0330">LINC01413 RNA was transcribed with T7 RNA polymerase (Roche) and then biotin labeled using biotin RNA labeling mix (Roche). The RNA pull-down assay was carried out by using a magnetic RNA-protein pull-down kit (Thermo Fisher Scientific) on the basis of the manufacturer&#x02019;s instructions. Biotinylated LINC01413 was hatched at 4&#x000b0;C with streptavidin beads overnight. After adding cell lysate, the system was incubated for another 4&#x000a0;h at 4&#x000b0;C. Then, beads were washed three times and the level of hnRNP-K protein in the eluted complex was analyzed using western blotting.</p></sec><sec id="sec4.14"><title>RIP Assays</title><p id="p0335">RIP experiments were carried out by using a Magna RIP RNA-binding protein immunoprecipitation kit (Millipore, USA) under the manufacturer&#x02019;s protocols. hnRNP-K antibody for the RIP assay was purchased from Abcam (Cambridge, MA, USA).</p></sec><sec id="sec4.15"><title>CoIP Assay</title><p id="p0340">Cells were lysed with lysis buffer (50&#x000a0;mmol/L Tris-HCl [pH 7.5], 150&#x000a0;mmol/L NaCl, 0.2% Nonidet P-40, 5% glycerol, 1% [v/v] Tween 20, protease inhibitor cocktail [Roche]). Then, the cell lysates were centrifuged at 12,000&#x000a0;&#x000d7; <italic>g</italic> at 4&#x000b0;C for 10&#x000a0;min and incubated with hnRNP-K antibody (ab52600, Abcam) at 4&#x000b0;C for 3 h. After that, protein A/G Sepharose beads (Santa Cruz) were added and incubated overnight. On the next day, the Sepharose beads were washed three times using lysis buffer, and the proteins or RNAs immunoprecipitated by hnRNP-K were determined using western blot or northern blot analysis.</p></sec><sec id="sec4.16"><title>FISH</title><p id="p0345">FISH assays were carried out as previously described.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref></p></sec><sec id="sec4.17"><title>Western Blot</title><p id="p0350">The proteins isolated from cells were separated using 10% SDS-PAGE and then transmitted to nitrocellulose (NC) membranes (Sigma, San Francisco, CA, USA). After that, the membranes were incubated with primary antibodies overnight, followed by incubation of horseradish peroxidase (HRP)-conjugated secondary antibodies (no. ab6728, 1:5,000; Abcam, UK) for another 1 h. The primary antibodies used in this study are as follows: anti-E-cadherin (no. 14472, 1:1,000), anti-&#x003b2;-catenin (no. 8480, 1:1,000), anti-N-cadherin (no. 13116, 1:1,000), anti-hnRNP-K (no. 9081, 1:1,000), anti-YAP (no. 14074, 1:1,000), anti-phospho-YAP (Ser<sup>127</sup>) (no. 13008, 1:1,000), anti-TAZ (no. 70148, 1:1,000), anti-phospho-TAZ (Ser<sup>89</sup>) (no. 59971, 1:1,000) (all of the above were purchased from Cell Signaling Technology, Boston, MA, USA); anti-Vimentin (sc-66002, 1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-ZEB1 (A301-921A, 1:2,000; Bethyl Laboratories, USA); and anti-GAPDH (G5262, 1:1,000; Sigma-Aldrich). GAPDH served as a normalized control, and proteins were captured using SuperSignal chemiluminescence substrate (Pierce, Thermo Scientific, Waltham, MA, USA) and analyzed by ImageJ (National Institutes of Health, USA).</p></sec><sec id="sec4.18"><title>Luciferase Reporter Assay</title><p id="p0355">For luciferase reporter experiments, sequences of the ZEB1 promoter were constructed into a pGL3 vector (Promega, Madison, WI, USA). Then, pcDNA3.1, pcDNA3.1/YAP1, or pcDNA3.1/TAZ1 was respectively transfected into the HEK293T cells together with pGL3-ZEB1 promoter, using Lipofectamine 2000 (Invitrogen). 48&#x000a0;h after transfection, the luciferase activity was evaluated by the use of an AutoLumat LB953 luminometer (Berthold).</p></sec><sec id="sec4.19"><title>Statistical Analysis</title><p id="p0360">All data were analyzed by using GraphPad Prism 6 or SPSS 20 (IBM, USA). Differences among groups were determined using a Student&#x02019;s t&#x000a0;test, the Wilcoxon signed-rank test, Pearson&#x02019;s chi-square test, Pearson correlation analysis, or the nonparametric Mann-Whitney U test, as required. Kaplan-Meier analysis (log-rank test) was used to evaluate the overall survival of CRC patients. The relationship among genes was detected by Spearman&#x02019;s correlation analysis. Statistical significance was reached when differences were expressed with p values &#x0003c;0.05.</p></sec></sec><sec id="sec5"><title>Author Contributions</title><p id="p0365">L. Ji designed this study. L. Ji, X.L., and Z. Zhou performed experiments, interpreted results of experiments, and analyzed data. L. Ji, Z. Zheng, L. Jin, and F.J. prepared figures and drafted the manuscript. All authors approved the final version of the manuscript.</p></sec><sec id="sec6"><title>Conflicts of Interest</title><p id="p0370">The authors declare no competing interests.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Zou</surname><given-names>Z.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer statistics, 2014</article-title><source>CA Cancer J. Clin.</source><volume>64</volume><year>2014</year><fpage>9</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">24399786</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Loree</surname><given-names>J.M.</given-names></name><name><surname>Kopetz</surname><given-names>S.</given-names></name></person-group><article-title>Recent developments in the treatment of metastatic colorectal cancer</article-title><source>Ther. Adv. Med. Oncol.</source><volume>9</volume><year>2017</year><fpage>551</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">28794806</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Gkolfakis</surname><given-names>P.</given-names></name><name><surname>Tziatzios</surname><given-names>G.</given-names></name><name><surname>Dimitriadis</surname><given-names>G.D.</given-names></name><name><surname>Triantafyllou</surname><given-names>K.</given-names></name></person-group><article-title>New endoscopes and add-on devices to improve colonoscopy performance</article-title><source>World J. Gastroenterol.</source><volume>23</volume><year>2017</year><fpage>3784</fpage><lpage>3796</lpage><pub-id pub-id-type="pmid">28638218</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>A.</given-names></name><name><surname>Pathak</surname><given-names>S.</given-names></name><name><surname>Subramanium</surname><given-names>V.D.</given-names></name><name><surname>G</surname><given-names>D.</given-names></name><name><surname>Murugesan</surname><given-names>R.</given-names></name><name><surname>Verma</surname><given-names>R.S.</given-names></name></person-group><article-title>Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives</article-title><source>Drug Discov. Today</source><volume>22</volume><year>2017</year><fpage>1224</fpage><lpage>1232</lpage><pub-id pub-id-type="pmid">28545838</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>G.P.</given-names></name><name><surname>Massagu&#x000e9;</surname><given-names>J.</given-names></name></person-group><article-title>Cancer metastasis: building a framework</article-title><source>Cell</source><volume>127</volume><year>2006</year><fpage>679</fpage><lpage>695</lpage><pub-id pub-id-type="pmid">17110329</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Marchese</surname><given-names>F.P.</given-names></name><name><surname>Raimondi</surname><given-names>I.</given-names></name><name><surname>Huarte</surname><given-names>M.</given-names></name></person-group><article-title>The multidimensional mechanisms of long noncoding RNA function</article-title><source>Genome Biol.</source><volume>18</volume><year>2017</year><fpage>206</fpage><pub-id pub-id-type="pmid">29084573</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Morlando</surname><given-names>M.</given-names></name><name><surname>Fatica</surname><given-names>A.</given-names></name></person-group><article-title>Alteration of epigenetic regulation by long noncoding RNAs in cancer</article-title><source>Int. J. Mol. Sci.</source><volume>19</volume><year>2018</year><fpage>E570</fpage><pub-id pub-id-type="pmid">29443889</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Noh</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>K.M.</given-names></name><name><surname>McClusky</surname><given-names>W.G.</given-names></name><name><surname>Abdelmohsen</surname><given-names>K.</given-names></name><name><surname>Gorospe</surname><given-names>M.</given-names></name></person-group><article-title>Cytoplasmic functions of long noncoding RNAs</article-title><source>Wiley Interdiscip. Rev. RNA</source><volume>9</volume><year>2018</year><fpage>e1471</fpage><pub-id pub-id-type="pmid">29516680</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>A.M.</given-names></name><name><surname>Chang</surname><given-names>H.Y.</given-names></name></person-group><article-title>Long noncoding RNAs in cancer pathways</article-title><source>Cancer Cell</source><volume>29</volume><year>2016</year><fpage>452</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">27070700</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Mitra</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Greenawalt</surname><given-names>E.J.</given-names></name><name><surname>Maulik</surname><given-names>U.</given-names></name><name><surname>Jiang</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Eischen</surname><given-names>C.M.</given-names></name></person-group><article-title>Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition</article-title><source>Nat. Commun.</source><volume>8</volume><year>2017</year><fpage>1604</fpage><pub-id pub-id-type="pmid">29150601</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Ding</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Tian</surname><given-names>L.</given-names></name><name><surname>Yuan</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Shi</surname><given-names>G.</given-names></name></person-group><article-title>Long non-coding RNA XLOC_000647 suppresses progression of pancreatic cancer and decreases epithelial-mesenchymal transition-induced cell invasion by down-regulating NLRP3</article-title><source>Mol. Cancer</source><volume>17</volume><year>2018</year><fpage>18</fpage><pub-id pub-id-type="pmid">29386037</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>lncRNA TUG1 promoted KIAA1199 expression via miR-600 to accelerate cell metastasis and&#x000a0;epithelial-mesenchymal transition in colorectal cancer</article-title><source>J.&#x000a0;Exp. Clin. Cancer Res.</source><volume>37</volume><year>2018</year><fpage>106</fpage><pub-id pub-id-type="pmid">29776371</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>J.</given-names></name><name><surname>Sun</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Wan</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>E.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Lai</surname><given-names>M.</given-names></name></person-group><article-title>Long non-coding RNA LINC01133 inhibits epithelial-mesenchymal transition and metastasis in colorectal cancer by interacting with SRSF6</article-title><source>Cancer Lett.</source><volume>380</volume><year>2016</year><fpage>476</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">27443606</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>J.H.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name></person-group><article-title>Epithelial-mesenchymal plasticity in carcinoma metastasis</article-title><source>Genes Dev.</source><volume>27</volume><year>2013</year><fpage>2192</fpage><lpage>2206</lpage><pub-id pub-id-type="pmid">24142872</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>D.</given-names></name><name><surname>Dai</surname><given-names>C.</given-names></name><name><surname>Peng</surname><given-names>S.</given-names></name></person-group><article-title>Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation</article-title><source>Mol. Cancer Res.</source><volume>9</volume><year>2011</year><fpage>1608</fpage><lpage>1620</lpage><pub-id pub-id-type="pmid">21840933</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Scheel</surname><given-names>C.</given-names></name><name><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links</article-title><source>Semin. Cancer Biol.</source><volume>22</volume><year>2012</year><fpage>396</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">22554795</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>De Craene</surname><given-names>B.</given-names></name><name><surname>Berx</surname><given-names>G.</given-names></name></person-group><article-title>Regulatory networks defining EMT during cancer initiation and progression</article-title><source>Nat. Rev. Cancer</source><volume>13</volume><year>2013</year><fpage>97</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">23344542</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name></person-group><article-title>ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance</article-title><source>Cell Cycle</source><volume>14</volume><year>2015</year><fpage>481</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">25607528</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Jia</surname><given-names>L.T.</given-names></name><name><surname>Yang</surname><given-names>A.G.</given-names></name></person-group><article-title>Missing links in epithelial-mesenchymal transition: long non-coding RNAs enter the arena</article-title><source>Cell. Physiol. Biochem.</source><volume>44</volume><year>2017</year><fpage>1665</fpage><lpage>1680</lpage><pub-id pub-id-type="pmid">29216625</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>D.M.</given-names></name><name><surname>Medici</surname><given-names>D.</given-names></name></person-group><article-title>Signaling mechanisms of the epithelial-mesenchymal transition</article-title><source>Sci. Signal.</source><volume>7</volume><year>2014</year><fpage>re8</fpage><pub-id pub-id-type="pmid">25249658</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>H.Y.</given-names></name><name><surname>Fattet</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name></person-group><article-title>Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis</article-title><source>Clin. Cancer Res.</source><volume>21</volume><year>2015</year><fpage>962</fpage><lpage>968</lpage><pub-id pub-id-type="pmid">25107915</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Deng</surname><given-names>F.</given-names></name><name><surname>Qin</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Xing</surname><given-names>Z.</given-names></name><name><surname>Ji</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>Q.J.</given-names></name></person-group><article-title>Long non-coding RNA regulation of epithelial-mesenchymal transition in cancer metastasis</article-title><source>Cell Death Dis.</source><volume>7</volume><year>2016</year><fpage>e2254</fpage><pub-id pub-id-type="pmid">27277676</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>X.M.</given-names></name></person-group><article-title>MicroRNAs: regulators of cancer metastasis and epithelial-mesenchymal transition (EMT)</article-title><source>Chin. J. Cancer</source><volume>33</volume><year>2014</year><fpage>140</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">24016392</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>P.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Yao</surname><given-names>R.</given-names></name><name><surname>Ma</surname><given-names>M.</given-names></name><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name></person-group><article-title>lincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis</article-title><source>Cell Death Dis.</source><volume>5</volume><year>2014</year><fpage>e1287</fpage><pub-id pub-id-type="pmid">24922071</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>K.F.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Thomas</surname><given-names>D.M.</given-names></name></person-group><article-title>The Hippo pathway and human cancer</article-title><source>Nat. Rev. Cancer</source><volume>13</volume><year>2013</year><fpage>246</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">23467301</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>D.</given-names></name></person-group><article-title>The Hippo signaling pathway in development and cancer</article-title><source>Dev. Cell</source><volume>19</volume><year>2010</year><fpage>491</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">20951342</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Zanconato</surname><given-names>F.</given-names></name><name><surname>Cordenonsi</surname><given-names>M.</given-names></name><name><surname>Piccolo</surname><given-names>S.</given-names></name></person-group><article-title>YAP/TAZ at the roots of cancer</article-title><source>Cancer Cell</source><volume>29</volume><year>2016</year><fpage>783</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">27300434</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B.</given-names></name><name><surname>Lei</surname><given-names>Q.-Y.</given-names></name><name><surname>Guan</surname><given-names>K.-L.</given-names></name></person-group><article-title>The Hippo-YAP pathway: new connections between regulation of organ size and cancer</article-title><source>Curr. Opin. Cell Biol.</source><volume>20</volume><year>2008</year><fpage>638</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">18955139</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>A.W.</given-names></name><name><surname>Meng</surname><given-names>Z.</given-names></name><name><surname>Guan</surname><given-names>K.-L.</given-names></name></person-group><article-title>The Hippo pathway in intestinal regeneration and disease</article-title><source>Nat. Rev. Gastroenterol. Hepatol</source><volume>13</volume><year>2016</year><fpage>324</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">27147489</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Yuen</surname><given-names>H.F.</given-names></name><name><surname>McCrudden</surname><given-names>C.M.</given-names></name><name><surname>Huang</surname><given-names>Y.H.</given-names></name><name><surname>Tham</surname><given-names>J.M.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zeng</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>S.D.</given-names></name><name><surname>Hong</surname><given-names>W.</given-names></name></person-group><article-title>TAZ expression as a prognostic indicator in colorectal cancer</article-title><source>PLoS ONE</source><volume>8</volume><year>2013</year><fpage>e54211</fpage><pub-id pub-id-type="pmid">23372686</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>L.A.</given-names></name><name><surname>Bray</surname><given-names>F.</given-names></name><name><surname>Siegel</surname><given-names>R.L.</given-names></name><name><surname>Ferlay</surname><given-names>J.</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Global cancer statistics, 2012</article-title><source>CA Cancer J. Clin.</source><volume>65</volume><year>2015</year><fpage>87</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">25651787</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R.L.</given-names></name><name><surname>Ward</surname><given-names>E.M.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992&#x02013;2008</article-title><source>Cancer Epidemiol. Biomarkers Prev.</source><volume>21</volume><year>2012</year><fpage>411</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">22219318</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Aizer</surname><given-names>A.A.</given-names></name><name><surname>Chen</surname><given-names>M.H.</given-names></name><name><surname>McCarthy</surname><given-names>E.P.</given-names></name><name><surname>Mendu</surname><given-names>M.L.</given-names></name><name><surname>Koo</surname><given-names>S.</given-names></name><name><surname>Wilhite</surname><given-names>T.J.</given-names></name><name><surname>Graham</surname><given-names>P.L.</given-names></name><name><surname>Choueiri</surname><given-names>T.K.</given-names></name><name><surname>Hoffman</surname><given-names>K.E.</given-names></name><name><surname>Martin</surname><given-names>N.E.</given-names></name></person-group><article-title>Marital status and survival in patients with cancer</article-title><source>J.&#x000a0;Clin. Oncol.</source><volume>31</volume><year>2013</year><fpage>3869</fpage><lpage>3876</lpage><pub-id pub-id-type="pmid">24062405</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D.L.</given-names></name><name><surname>Lu</surname><given-names>Y.X.</given-names></name><name><surname>Zhang</surname><given-names>J.X.</given-names></name><name><surname>Wei</surname><given-names>X.L.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Zeng</surname><given-names>Z.L.</given-names></name><name><surname>Pan</surname><given-names>Z.Z.</given-names></name><name><surname>Yuan</surname><given-names>Y.F.</given-names></name><name><surname>Wang</surname><given-names>F.H.</given-names></name><name><surname>Pelicano</surname><given-names>H.</given-names></name></person-group><article-title>Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression</article-title><source>Theranostics</source><volume>7</volume><year>2017</year><fpage>4836</fpage><lpage>4849</lpage><pub-id pub-id-type="pmid">29187907</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Dasgupta</surname><given-names>P.</given-names></name><name><surname>Kulkarni</surname><given-names>P.</given-names></name><name><surname>Majid</surname><given-names>S.</given-names></name><name><surname>Shahryari</surname><given-names>V.</given-names></name><name><surname>Hashimoto</surname><given-names>Y.</given-names></name><name><surname>Bhat</surname><given-names>N.S.</given-names></name><name><surname>Shiina</surname><given-names>M.</given-names></name><name><surname>Deng</surname><given-names>G.</given-names></name><name><surname>Saini</surname><given-names>S.</given-names></name><name><surname>Tabatabai</surname><given-names>Z.L.</given-names></name></person-group><article-title>MicroRNA-203 inhibits long noncoding RNA HOTAIR and regulates tumorigenesis through epithelial-to-mesenchymal transition pathway in renal cell carcinoma</article-title><source>Mol. Cancer Ther.</source><volume>17</volume><year>2018</year><fpage>1061</fpage><lpage>1069</lpage><pub-id pub-id-type="pmid">29440295</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Z.Q.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>Q.B.</given-names></name><name><surname>Liu</surname><given-names>J.B.</given-names></name><name><surname>Yang</surname><given-names>S.X.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Ou</surname><given-names>C.L.</given-names></name><name><surname>Sun</surname><given-names>X.T.</given-names></name><name><surname>Wang</surname><given-names>G.X.</given-names></name><name><surname>Song</surname><given-names>J.M.</given-names></name></person-group><article-title>Long non-coding RNA LINC00959 predicts colorectal cancer patient prognosis and inhibits tumor progression</article-title><source>Oncotarget</source><volume>8</volume><year>2017</year><fpage>97052</fpage><lpage>97060</lpage><pub-id pub-id-type="pmid">29228592</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Caramel</surname><given-names>J.</given-names></name><name><surname>Ligier</surname><given-names>M.</given-names></name><name><surname>Puisieux</surname><given-names>A.</given-names></name></person-group><article-title>Pleiotropic roles for ZEB1 in cancer</article-title><source>Cancer Res.</source><volume>78</volume><year>2018</year><fpage>30</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">29254997</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Dhamija</surname><given-names>S.</given-names></name><name><surname>Diederichs</surname><given-names>S.</given-names></name></person-group><article-title>From junk to master regulators of invasion: lncRNA functions in migration, EMT and metastasis</article-title><source>Int. J. Cancer</source><volume>139</volume><year>2016</year><fpage>269</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">26875870</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Cui</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Zeng</surname><given-names>J.</given-names></name></person-group><article-title>lncRNA NKILA suppresses TGF-&#x003b2;-induced epithelial-mesenchymal transition by blocking NF-&#x003ba;B signaling in breast cancer</article-title><source>Int. J. Cancer</source><volume>143</volume><year>2018</year><fpage>2213</fpage><lpage>2224</lpage><pub-id pub-id-type="pmid">29761481</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Taha</surname><given-names>Z.</given-names></name><name><surname>Janse van Rensburg</surname><given-names>H.J.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>The Hippo pathway: immunity and cancer</article-title><source>Cancers (Basel)</source><volume>10</volume><year>2018</year><fpage>E94</fpage><pub-id pub-id-type="pmid">29597279</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>B.</given-names></name><name><surname>Billaud</surname><given-names>M.</given-names></name><name><surname>Almeida</surname><given-names>R.</given-names></name></person-group><article-title>RNA-binding proteins in cancer: old players and new actors</article-title><source>Trends Cancer</source><volume>3</volume><year>2017</year><fpage>506</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">28718405</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Gallardo</surname><given-names>M.</given-names></name><name><surname>Hornbaker</surname><given-names>M.J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>P.</given-names></name><name><surname>Bueso-Ramos</surname><given-names>C.</given-names></name><name><surname>Post</surname><given-names>S.M.</given-names></name></person-group><article-title>Aberrant hnRNP K expression: all roads lead to cancer</article-title><source>Cell Cycle</source><volume>15</volume><year>2016</year><fpage>1552</fpage><lpage>1557</lpage><pub-id pub-id-type="pmid">27049467</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Aboushousha</surname><given-names>T.</given-names></name><name><surname>Hammam</surname><given-names>O.</given-names></name><name><surname>Helal</surname><given-names>N.</given-names></name><name><surname>El Dahshan</surname><given-names>S.</given-names></name></person-group><article-title>Impact of cyclin D1 and heterogeneous nuclear ribonucleoprotein-K (HnRNP-K) on urinary bladder carcinogenesis</article-title><source>Asian Pac. J. Cancer Prev.</source><volume>19</volume><year>2018</year><fpage>513</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">29480994</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>F.H.</given-names></name></person-group><article-title>Role and molecular mechanism of heterogeneous nuclear ribonucleoprotein K in tumor development and progression</article-title><source>Biomed. Rep.</source><volume>4</volume><year>2016</year><fpage>657</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">27284403</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Chang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Long non-coding RNA CASC11 interacts with hnRNP-K and activates the WNT/&#x003b2;-catenin pathway to promote growth and metastasis in colorectal cancer</article-title><source>Cancer Lett.</source><volume>376</volume><year>2016</year><fpage>62</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">27012187</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Gallardo</surname><given-names>M.</given-names></name><name><surname>Lee</surname><given-names>H.J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Bueso-Ramos</surname><given-names>C.</given-names></name><name><surname>Pageon</surname><given-names>L.R.</given-names></name><name><surname>McArthur</surname><given-names>M.</given-names></name><name><surname>Multani</surname><given-names>A.</given-names></name><name><surname>Nazha</surname><given-names>A.</given-names></name><name><surname>Manshouri</surname><given-names>T.</given-names></name><name><surname>Parker-Thornburg</surname><given-names>J.</given-names></name></person-group><article-title>hnRNP K is a haploinsufficient tumor suppressor that regulates proliferation and differentiation programs in hematologic malignancies</article-title><source>Cancer Cell</source><volume>28</volume><year>2015</year><fpage>486</fpage><lpage>499</lpage><pub-id pub-id-type="pmid">26412324</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Bomsztyk</surname><given-names>K.</given-names></name><name><surname>Denisenko</surname><given-names>O.</given-names></name><name><surname>Ostrowski</surname><given-names>J.</given-names></name></person-group><article-title>hnRNP K: one protein multiple processes</article-title><source>BioEssays</source><volume>26</volume><year>2004</year><fpage>629</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">15170860</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Bomsztyk</surname><given-names>K.</given-names></name><name><surname>Van Seuningen</surname><given-names>I.</given-names></name><name><surname>Suzuki</surname><given-names>H.</given-names></name><name><surname>Denisenko</surname><given-names>O.</given-names></name><name><surname>Ostrowski</surname><given-names>J.</given-names></name></person-group><article-title>Diverse molecular interactions of the hnRNP K protein</article-title><source>FEBS Lett.</source><volume>403</volume><year>1997</year><fpage>113</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">9042948</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>F.</given-names></name><name><surname>Bao</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>A.</given-names></name></person-group><article-title>A feed-forward loop between lncARSR and YAP activity promotes expansion of renal tumour-initiating cells</article-title><source>Nat. Commun.</source><volume>7</volume><year>2016</year><fpage>12692</fpage><pub-id pub-id-type="pmid">27886176</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Fang</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Dong</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>K.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Xiao</surname><given-names>Z.</given-names></name></person-group><article-title>lncRNA B4GALT1-AS1 promotes colon cancer cell stemness and migration by recruiting YAP to the nucleus and enhancing YAP transcriptional activity</article-title><source>J.&#x000a0;Cell. Physiol.</source><volume>234</volume><year>2019</year><fpage>18524</fpage><lpage>18534</lpage><pub-id pub-id-type="pmid">30912138</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>X.</given-names></name><name><surname>Spindler</surname><given-names>T.J.</given-names></name><name><surname>de Souza Fonseca</surname><given-names>M.A.</given-names></name><name><surname>Corona</surname><given-names>R.I.</given-names></name><name><surname>Seo</surname><given-names>J.-H.</given-names></name><name><surname>Dezem</surname><given-names>F.S.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Lee</surname><given-names>J.M.</given-names></name><name><surname>Long</surname><given-names>H.W.</given-names></name><name><surname>Sellers</surname><given-names>T.A.</given-names></name></person-group><article-title>Super-enhancer-associated lncRNA UCA1 with AMOT to activate YAP target genes in epithelial ovarian cancer</article-title><source>iScience</source><volume>17</volume><year>2019</year><fpage>242</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">31307004</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Ashburner</surname><given-names>M.</given-names></name><name><surname>Ball</surname><given-names>C.A.</given-names></name><name><surname>Blake</surname><given-names>J.A.</given-names></name><name><surname>Botstein</surname><given-names>D.</given-names></name><name><surname>Butler</surname><given-names>H.</given-names></name><name><surname>Cherry</surname><given-names>J.M.</given-names></name><name><surname>Davis</surname><given-names>A.P.</given-names></name><name><surname>Dolinski</surname><given-names>K.</given-names></name><name><surname>Dwight</surname><given-names>S.S.</given-names></name><name><surname>Eppig</surname><given-names>J.T.</given-names></name><collab>The Gene Ontology Consortium</collab></person-group><article-title>Gene ontology: tool for the unification of biology</article-title><source>Nat. Genet.</source><volume>25</volume><year>2000</year><fpage>25</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">10802651</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>J.F.</given-names></name><name><surname>Yin</surname><given-names>Q.F.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.O.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>H.B.</given-names></name><name><surname>Ge</surname><given-names>J.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name></person-group><article-title>Human colorectal cancer-specific CCAT1-L lncRNA regulates long-range chromatin interactions at the <italic>MYC</italic> locus</article-title><source>Cell Res.</source><volume>24</volume><year>2014</year><fpage>513</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">24662484</pub-id></element-citation></ref></ref-list><sec id="appsec2" sec-type="supplementary-material"><title>Supplemental Information</title><p id="p0385"><supplementary-material content-type="local-data" id="mmc1"><caption><title>Document S1. Figures S1&#x02013;S5</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="mmc2"><caption><title>Document S2. Article plus Supplemental Information</title></caption><media xlink:href="mmc2.pdf"/></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgments</title><p>This research is supported by <funding-source id="gs1">Natural Science Foundation of Zhejiang Province</funding-source> (LY15C070003).</p></ack><fn-group><fn id="appsec1" fn-type="supplementary-material"><p id="p0380">Supplemental Information can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.omtn.2019.11.027" id="intref0040">https://doi.org/10.1016/j.omtn.2019.11.027</ext-link>.</p></fn></fn-group></back></article>